Optinose Completes Patient Recruitment in Second Pivotal Trial for XHANCE in Chronic Sinusitis
28 oct. 2021 06h59 HE
|
Optinose, Inc.
Company Expects Top-Line Results in Second Quarter 2022 XHANCE Reaches Important Milestone on Path to be the First FDA-Approved Drug Treatment for the Approximately 30 million Chronic Sinusitis...
Optinose to Present at the Cantor Virtual Global Healthcare Conference
22 sept. 2021 16h15 HE
|
Optinose, Inc.
YARDLEY, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
25 août 2021 17h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Aug. 25, 2021 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
11 août 2021 07h00 HE
|
Optinose, Inc.
Second quarter 2021 XHANCE net revenue of $18.4 million increased 79% compared to second quarter 2020 Second quarter 2021 XHANCE prescriptions increased 33% from second quarter 2020 Conference call...
Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis
30 juil. 2021 08h00 HE
|
Optinose, Inc.
Company Expects Top-Line Results in First Quarter 2022 XHANCE Reaches Important Milestone on Path to be the First FDA-Approved Drug Treatment for the Approximately 30 million Chronic Sinusitis...
Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million
28 juil. 2021 08h00 HE
|
Optinose, Inc.
Preliminary XHANCE Net Revenue Growth of 79% Compared to Second Quarter 2020 Company reiterates XHANCE Net Revenue guidance for the Full Year of 2021 to be at least $80 million Conference Call and...
Optinose Technology Inventor Per Djupesland Named Winner of European Inventor Award 2021 for Industry
24 juin 2021 08h00 HE
|
Optinose, Inc.
YARDLEY, Pa., June 24, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Present at the Jefferies Virtual Healthcare Conference
01 juin 2021 09h00 HE
|
Optinose, Inc.
YARDLEY, Pa., June 01, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports First Quarter 2021 Financial Results and Operational Updates
05 mai 2021 07h00 HE
|
Optinose, Inc.
Company reports first quarter total revenue of $12.0 million First quarter 2021 XHANCE net revenue of $11.0 million increased 55% compared to first quarter 2020 Conference call and webcast to be...
Optinose Announces Reporting Date for First Quarter 2021 Financial Results and Upcoming Healthcare Conference Presentation
28 avr. 2021 08h30 HE
|
Optinose, Inc.
Conference Call and Webcast to be held May 5, 2021 at 8:00 a.m. Eastern Time Company to Present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021 YARDLEY, Pa., April 28, 2021...